InspireMD's Losses Widen Despite Revenue Growth, Liquidity Concerns Mount

TL;DR

**InspireMD is burning cash at an alarming rate despite revenue growth, making it a high-risk bet on future capital raises and CGuard Prime's profitability.**

AI Summary

InspireMD, Inc. reported a significant increase in revenue for the three and nine months ended September 30, 2025, reaching $2.523 million and $5.830 million, respectively, up from $1.810 million and $5.060 million in the prior year periods. Despite this revenue growth, the company experienced a substantial increase in net loss, with a net loss of $12.708 million for the three months ended September 30, 2025, compared to $7.890 million in the same period of 2024, and a net loss of $37.025 million for the nine months ended September 30, 2025, up from $22.831 million in 2024. This widening loss is primarily driven by a surge in operating expenses, particularly selling and marketing expenses which rose to $4.392 million for the quarter and $11.314 million for the nine months in 2025, compared to $1.472 million and $4.154 million in 2024. General and administrative expenses also increased to $5.888 million for the quarter and $16.157 million for the nine months in 2025. The company successfully raised $55.569 million in financing activities during the nine months ended September 30, 2025, significantly boosting its cash and cash equivalents to $63.403 million from $18.916 million at December 31, 2024. However, InspireMD continues to operate with an accumulated deficit of $290.531 million and negative operating cash flows, leading to substantial doubt about its ability to continue as a going concern for at least the next 12 months.

Why It Matters

InspireMD's increased revenue, driven by the commercial launch of CGuard Prime, signals potential market traction for its MicroNet stent technology, which is crucial for a medical device company. However, the escalating net losses and operating expenses, particularly in selling and marketing, raise questions about the efficiency of their commercialization strategy and path to profitability. For investors, the 'going concern' warning is a critical red flag, indicating significant financial instability and reliance on future capital raises. Competitively, while CGuard Prime received key approvals, sustained losses could hinder its ability to compete effectively against larger, more established players in the vascular and coronary disease treatment market.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' due to a history of net losses and negative operating cash flows, and insufficient resources to fund operations for at least the next 12 months. The accumulated deficit reached $290.531 million as of September 30, 2025, and net cash used in operating activities was $25.758 million for the nine months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor future capital raises and the company's ability to significantly reduce its cash burn and achieve commercial profitability for CGuard EPS. Without a clear path to positive cash flow, further dilution or operational curtailment is likely.

Financial Highlights

debt To Equity

0.22

revenue

$5.830M

operating Margin

-644%

total Assets

$78.472M

total Debt

$14.358M

net Income

$(37.025)M

eps

$(0.64)

gross Margin

25.2%

cash Position

$63.403M

revenue Growth

+15.2%

Key Numbers

• $2.523M — Revenue for Q3 2025 (Increased from $1.810M in Q3 2024)
• $5.830M — Revenue for nine months ended Sep 30, 2025 (Increased from $5.060M in the prior year period)
• $(12.708)M — Net Loss for Q3 2025 (Worsened from $(7.890)M in Q3 2024)
• $(37.025)M — Net Loss for nine months ended Sep 30, 2025 (Worsened from $(22.831)M in the prior year period)
• $63.403M — Cash and cash equivalents as of Sep 30, 2025 (Significantly increased from $18.916M at Dec 31, 2024)
• $55.569M — Net cash provided by financing activities for nine months ended Sep 30, 2025 (Increased from $16.889M in the prior year period)
• $(290.531)M — Accumulated deficit as of Sep 30, 2025 (Increased from $(253.506)M at Dec 31, 2024)
• $(25.758)M — Net cash used in operating activities for nine months ended Sep 30, 2025 (Increased from $(15.118)M in the prior year period)
• $11.314M — Selling and marketing expenses for nine months ended Sep 30, 2025 (Increased from $4.154M in the prior year period)
• 41,919,141 — Common shares issued and outstanding as of Sep 30, 2025 (Increased from 26,611,033 at Dec 31, 2024, indicating dilution)

Key Players & Entities

• InspireMD, Inc. (company) — registrant of the 10-Q filing
• CGuard EPS (product) — company's primary carotid product
• CGuard Prime carotid stent system (product) — product that received CE Mark and FDA PMA approval
• U.S. Food and Drug Administration (regulator) — granted premarket application (PMA) approval for CGuard Prime
• Hamas (person) — terrorist organization involved in conflict with Israel
• Israel (country) — location of company's operations and conflict
• Iran (country) — involved in conflict with Israel
• Financial Accounting Standards Board (regulator) — issued accounting standards updates

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: InspireMD faces substantial doubt about its ability to continue as a going concern for at least the next 12 months due to persistent negative operating cash flows and a significant accumulated deficit of $290.531 million as of September 30, 2025. Despite recent financing, the company's operational losses continue to outpace its revenue generation.
• Increasing Operating Expenses [high — financial]: Operating expenses have surged, with selling and marketing expenses increasing from $4.154 million to $11.314 million and general and administrative expenses rising from $11.078 million to $16.157 million for the nine months ended September 30, 2025. This rapid escalation in costs, outpacing revenue growth, contributes significantly to the widening net loss.
• Dilution from Share Issuances [medium — financial]: The company has seen a significant increase in outstanding common shares from 26,611,033 at December 31, 2024, to 41,919,141 as of September 30, 2025. This substantial dilution, driven by financing activities including stock and warrant exercises, can negatively impact existing shareholders' value.
• Dependence on Financing [high — operational]: The company's ability to continue operations is heavily reliant on its success in raising capital through financing activities, as evidenced by the $55.569 million raised in the nine months ended September 30, 2025. Future access to capital markets remains a critical risk.

Industry Context

InspireMD operates in the highly competitive medical device sector, specifically focusing on neurovascular and cardiovascular interventions. The industry is characterized by rapid technological advancements, stringent regulatory approvals (e.g., FDA), and significant R&D investment. Companies often rely on strategic partnerships and substantial capital raises to fund product development and market penetration.

Regulatory Implications

As a medical device company, InspireMD is subject to rigorous regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, clinical trial requirements, and post-market surveillance is critical. Any failure to meet these standards can result in product recalls, fines, or market access restrictions, impacting financial performance and investor confidence.

What Investors Should Do

1. Monitor expense control and path to profitability.
2. Assess the sustainability of revenue growth.
3. Evaluate the impact of share dilution.
4. Analyze future financing needs and risks.

Key Dates

• 2025-09-30: Quarterly Period End — Reporting period for the 10-Q, showing increased revenue but a substantially widened net loss and a strong cash position due to financing.
• 2025-12-31: Prior Year End — Baseline for comparison of cash position and accumulated deficit.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a negative balance in retained earnings. (Indicates the company's long history of unprofitability, contributing to going concern doubts.)

Going concern

An accounting assumption that a company will continue to operate for the foreseeable future (typically at least 12 months). If there is substantial doubt, it must be disclosed. (The company explicitly states substantial doubt about its ability to continue as a going concern, a critical warning for investors.)

Dilution

The reduction in the value of existing shareholders' equity resulting from the issuance of new shares. (The significant increase in outstanding shares indicates potential dilution for current investors.)

Operating Expenses

Costs incurred by a company in its normal business operations, excluding cost of goods sold. Includes R&D, selling & marketing, and G&A. (The sharp rise in operating expenses is the primary driver of the increased net loss.)

Year-Over-Year Comparison

Compared to the prior year periods, InspireMD has demonstrated robust revenue growth, with Q3 2025 revenue up 39.4% and nine-month revenue up 15.2%. However, this top-line improvement has been overshadowed by a dramatic increase in operating expenses, leading to a significantly wider net loss for both the quarter and the nine-month period. While the company has substantially bolstered its cash reserves through successful financing activities, its accumulated deficit has also grown, and the risk of not being a going concern has intensified.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share NSPR Nasdaq Capital Mark
• $1 thousand — ,807 * Represents an amount less than $1 thousand The accompanying notes are an integra

Filing Documents

• form10-q.htm (10-Q) — 856KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-25-021503.txt ( ) — 4258KB
• nspr-20250930.xsd (EX-101.SCH) — 33KB
• nspr-20250930_cal.xml (EX-101.CAL) — 49KB
• nspr-20250930_def.xml (EX-101.DEF) — 119KB
• nspr-20250930_lab.xml (EX-101.LAB) — 272KB
• nspr-20250930_pre.xml (EX-101.PRE) — 209KB
• form10-q_htm.xml (XML) — 576KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 6303 Waterford District Drive Suite 215 Miami , Florida 33126 (Address of principal executive offices) (Zip Code) (888) 776-6804 (Registrant's telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Non-accelerated reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share NSPR Nasdaq Capital Market The number of shares of the registrant's common stock, $ 0.0001 par value, outstanding as of November 10, 2025: 42,370,995 Item 1. Financial Statements INSPIREMD, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE QUARTER ENDED SEPTEMBER 30, 2025 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED): Condensed Consolidated Balance Sheets F-2 - F-3 Condensed Consolidated Statements of Operations F-4 Condensed Consolidated Statements of Changes in Equity F-5 - F-8 Condensed Consolidated Statements of Cash Flows F-9 Notes to the Condensed Consolidated Financial Statements F-10 - F-18 F-1 INSPIREMD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (U.S. dollars in thousands, except share and per share data) September 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 63,403 $ 18,916 Marketable securities - 15,721 Accounts receivable: Trade, net 1,961 1,572 Other 475 682 Prepaid expenses 945 1,060 Inventory 3,607 2,570 TOTAL CURRENT ASSETS 70,391 40,521 NON-CURRENT ASSETS: Long term deposit 438 426 Property, plant and equipment, net 3,403 2,371 Operating lease right of use assets 2,915 2,360 Fund in respect of employee rights upon retirement 1,325 1,129 TOTAL NON-CURRENT ASSETS 8,081 6,286 TOTAL ASSETS $ 78,472 $ 46,807 F-2 INSPIREMD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (U.S. dollars in thousands other than share and per share data) September 30, December 31, 2025 2024 LIABILITIES AND EQUITY CURRENT LIABILITIES: Accounts payable and accruals: Trade 1,753 1,254 Other 9,063 6,424 TOTAL CURRENT LIABILITIES 10,816 7,678 LONG-TERM LIABILITIES- Operating lease liabilities net of current maturities 2,367 1,796 Liability for employees' rights upon retirement and others 1,175 1,247 TOTAL LONG-TERM LIABILITIES 3,542 3,043 TOTAL LIABILITIES 14,358 10,721 COMMITMENTS AND CONTINGENT LIABILITIES - - EQUITY: Common stock, par value $ 0.0001 per share; 150,000,000 shares authorized at September 30, 2025 and December 31, 2024; 41,919,141 and 26,611,033 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 4 3 Preferred C shares, par value $ 0.0001 per share; 1,172,000 shares authorized at September 30, 2025 and December 31, 2024; 1,718 shares issued and outstanding at September 30, 2025 and Decem

View Full Filing

View this 10-Q filing on SEC EDGAR